Cite
HARVARD Citation
Cadranel, J. et al. (n.d.). 3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience. European journal of cancer. pp. S616-S617. [Online].